Finally, we validated in the Memorial Sloan Kettering Cancer Center corhort (GSE248249) and Sjöberg Immune Checkpoint Inhibition cohort (GSE283829) that Cholescore was significantly decreased after PD-L1 treatment; additionally, compared with lung cancer patients with disease progression, those with stable disease also showed a decreasing trend in Cholescore (Fig. S2). The gene discussed is CD274; the disease is lung carcinoma.